8 results on '"Akil, Ammira S. Al-Shabeeb"'
Search Results
2. Deep learning-based identification of esophageal cancer subtypes through analysis of high-resolution histopathology images.
- Author
-
Aalam, Syed Wajid, Ahanger, Abdul Basit, Masoodi, Tariq A., Bhat, Ajaz A., Akil, Ammira S. Al-Shabeeb, Khan, Meraj Alam, Assad, Assif, Macha, Muzafar A., and Bhat, Muzafar Rasool
- Published
- 2024
- Full Text
- View/download PDF
3. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance.
- Author
-
Bhat, Gh Rasool, Sethi, Itty, Sadida, Hana Q., Rah, Bilal, Mir, Rashid, Algehainy, Naseh, Albalawi, Ibrahim Altedlawi, Masoodi, Tariq, Subbaraj, Gowtham Kumar, Jamal, Farrukh, Singh, Mayank, Kumar, Rakesh, Macha, Muzafar A., Uddin, Shahab, Akil, Ammira S. Al-Shabeeb, Haris, Mohammad, and Bhat, Ajaz A.
- Abstract
Cancer is a complex disease displaying a variety of cell states and phenotypes. This diversity, known as cancer cell plasticity, confers cancer cells the ability to change in response to their environment, leading to increased tumor diversity and drug resistance. This review explores the intricate landscape of cancer cell plasticity, offering a deep dive into the cellular, molecular, and genetic mechanisms that underlie this phenomenon. Cancer cell plasticity is intertwined with processes such as epithelial-mesenchymal transition and the acquisition of stem cell–like features. These processes are pivotal in the development and progression of tumors, contributing to the multifaceted nature of cancer and the challenges associated with its treatment. Despite significant advancements in targeted therapies, cancer cell adaptability and subsequent therapy-induced resistance remain persistent obstacles in achieving consistent, successful cancer treatment outcomes. Our review delves into the array of mechanisms cancer cells exploit to maintain plasticity, including epigenetic modifications, alterations in signaling pathways, and environmental interactions. We discuss strategies to counteract cancer cell plasticity, such as targeting specific cellular pathways and employing combination therapies. These strategies promise to enhance the efficacy of cancer treatments and mitigate therapy resistance. In conclusion, this review offers a holistic, detailed exploration of cancer cell plasticity, aiming to bolster the understanding and approach toward tackling the challenges posed by tumor heterogeneity and drug resistance. As articulated in this review, the delineation of cellular, molecular, and genetic mechanisms underlying tumor heterogeneity and drug resistance seeks to contribute substantially to the progress in cancer therapeutics and the advancement of precision medicine, ultimately enhancing the prospects for effective cancer treatment and patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
- Author
-
Dagar, Gunjan, Gupta, Ashna, Masoodi, Tariq, Nisar, Sabah, Merhi, Maysaloun, Hashem, Sheema, Chauhan, Ravi, Dagar, Manisha, Mirza, Sameer, Bagga, Puneet, Kumar, Rakesh, Akil, Ammira S. Al-Shabeeb, Macha, Muzafar A., Haris, Mohammad, Uddin, Shahab, Singh, Mayank, and Bhat, Ajaz A.
- Subjects
TUMOR treatment ,CELLULAR therapy ,TUMOR antigens ,CHIMERIC antigen receptors ,REACTIVE oxygen species ,DIFFUSE large B-cell lymphomas - Abstract
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
- Author
-
Dagar, Gunjan, Gupta, Ashna, Masoodi, Tariq, Nisar, Sabah, Merhi, Maysolun, Hashem, Sheema, Chauhan, Ravi, Dagar, Manisha, Mirza, Sameer, Bagga, Puneet, Kumar, Rakesh, Akil, Ammira S. Al-Shabeeb, Macha, Muzafar A., Haris, Mohammad, Uddin, Shahab, Singh, Mayank, and Bhat, Ajaz A.
- Subjects
TUMOR treatment ,MONOCLONAL antibodies ,BISPECIFIC antibodies ,CELLULAR therapy ,TUMOR antigens ,CHIMERIC antigen receptors ,REACTIVE oxygen species ,T cell receptors ,B cell receptors - Abstract
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Ubiquitin specific peptidase 37 and PCNA interaction promotes osteosarcoma pathogenesis by modulating replication fork progression.
- Author
-
Chauhan, Ravi, Gupta, Ashna, Malhotra, Lakshay, Bhat, Ajaz A., Pandita, Raj K., Masoodi, Tariq, Dagar, Gunjan, Sadida, Hana Q., Al-Marzooqi, Sara K., Batra, Atul, Bakhshi, Sameer, Sharma, Mehar Chand, Tanwar, Pranay, Khan, Shah Alam, Samath, Ethayathulla Abdul, Uddin, Shahab, Akil, Ammira S. Al-Shabeeb, Haris, Mohammad, Macha, Muzafar A., and Pandita, Tej K.
- Subjects
DEUBIQUITINATING enzymes ,PEPTIDASE ,DNA replication ,OSTEOSARCOMA ,PROLIFERATING cell nuclear antigen ,GENE expression ,GENETIC overexpression - Abstract
Background: Osteosarcoma is a type of bone cancer that predominantly affects young individuals, including children and adolescents. The disease progresses through heterogeneous genetic alterations, and patients often develop pulmonary metastases even after the primary tumors have been surgically removed. Ubiquitin-specific peptidases (USPs) regulate several critical cellular processes, such as cell cycle progression, transcriptional activation, and signal transduction. Various studies have revealed the significance of USP37 in the regulation of replication stress and oncogenesis. Methods: In this study, the Cancer Genome Atlas (TCGA) database was analyzed to investigate USP37 expression. RNA sequencing was utilized to assess the impact of USP37 overexpression and depletion on gene expression in osteosarcoma cells. Various molecular assays, including colony formation, immunofluorescence, immunoprecipitation, and DNA replication restart, were employed to examine the physical interaction between USP37 and PCNA, as well as its physiological effects in osteosarcoma cells. Additionally, molecular docking studies were conducted to gain insight into the nature of the interaction between USP37 and PCNA. Furthermore, immunohistochemistry was performed on archived tissue blocks from osteosarcoma patients to establish a correlation between USP37 and PCNA expression. Results: Analysis of the TCGA database revealed that increased expression of USP37 was linked to decreased progression-free survival (PFS) in osteosarcoma patients. Next-generation sequencing analysis of osteosarcoma cells demonstrated that overexpression or knockdown of USP37 led to the expression of different sets of genes. USP37 overexpression provided a survival advantage, while its depletion heightened sensitivity to replication stress in osteosarcoma cells. USP37 was found to physically interact with PCNA, and molecular docking studies indicated that the interaction occurs through unique residues. In response to genotoxic stress, cells that overexpressed USP37 resolved DNA damage foci more quickly than control cells or cells in which USP37 was depleted. The expression of USP37 varied in archived osteosarcoma tissues, with intermediate expression seen in 52% of cases in the cohort examined. Conclusion: The results of this investigation propose that USP37 plays a vital role in promoting replication stress tolerance in osteosarcoma cells. The interaction between USP37 and PCNA is involved in the regulation of replication stress, and disrupting it could potentially trigger synthetic lethality in osteosarcoma. This study has expanded our knowledge of the mechanism through which USP37 regulates replication stress, and its potential as a therapeutic target in osteosarcoma merits additional exploration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. The link between glycemic control measures and eye microvascular complications in a clinical cohort of type 2 diabetes with microRNA-223-3p signature.
- Author
-
Da’as, Sahar I., Ahmed, Ikhlak, Hasan, Waseem H., Abdelrahman, Doua A., Aliyev, Elbay, Nisar, Sabah, Bhat, Ajaz Ahmad, Joglekar, Mugdha V., Hardikar, Anandwardhan A., Fakhro, Khalid A., and Akil, Ammira S. Al-Shabeeb
- Abstract
Background: Type 2 diabetes (T2D) is a critical healthcare challenge and priority in Qatar which is listed amongst the top 10 countries in the world, with its prevalence presently at 17% double the global average. MicroRNAs (miRNAs) are implicated in the pathogenesis of (T2D) and long-term microvascular complications including diabetic retinopathy (DR). Methods: In this study, a T2D cohort that accurately matches the characteristics of the general population was employed to find microRNA (miRNA) signatures that are correlated with glycemic and β cell function measurements. Targeted miRNA profiling was performed in (471) T2D individuals with or without DR and (491) (non-diabetic) healthy controls from the Qatar Biobank. Discovery analysis identified 20 differentially expressed miRNAs in T2D compared to controls, of which miR-223-3p was significantly upregulated (fold change:5.16, p = 3.6e−02) and positively correlated with glucose and hemoglobin A1c (HbA1c) levels (p-value = 9.88e−04 and 1.64e−05, respectively), but did not show any significant associations with insulin or C-peptide. Accordingly, we performed functional validation using a miR-223-3p mimic (overexpression) under control and hyperglycemia-induced conditions in a zebrafish model. Results: Over-expression of miR-223-3p alone was associated with significantly higher glucose (42.7 mg/dL, n = 75 vs 38.7 mg/dL, n = 75, p = 0.02) and degenerated retinal vasculature, and altered retinal morphology involving changes in the ganglion cell layer and inner and outer nuclear layers. Assessment of retinal angiogenesis revealed significant upregulation in the expression of vascular endothelial growth factor and its receptors, including kinase insert domain receptor. Further, the pancreatic markers, pancreatic and duodenal homeobox 1, and the insulin gene expressions were upregulated in the miR-223-3p group. Conclusion: Our zebrafish model validates a novel correlation between miR-223-3p and DR development. Targeting miR-223-3p in T2D patients may serve as a promising therapeutic strategy to control DR in at-risk individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
- Author
-
Dagar, Gunjan, Gupta, Ashna, Masoodi, Tariq, Nisar, Sabah, Merhi, Maysaloun, Hashem, Sheema, Chauhan, Ravi, Dagar, Manisha, Mirza, Sameer, Bagga, Puneet, Kumar, Rakesh, Akil, Ammira S. Al-Shabeeb, Macha, Muzafar A., Haris, Mohammad, Uddin, Shahab, Singh, Mayank, and Bhat, Ajaz A.
- Subjects
TUMOR treatment ,CELLULAR therapy ,PERSONAL names - Abstract
Reference 1 Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, Kumar R. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments Tariq Masoodi, Sabah Nisar and Maysaloun Merhi have contributed equally. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.